Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia

Circulation Research

Volumn 109, Issue 6, 2011, Pages 712-713

  Watanabe, Hiroshi ^a   Steele, Derek S ^b   Knollmann, Björn C ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALSEQUESTRIN; FLECAINIDE; PROPAFENONE; RYANODINE RECEPTOR 2; SODIUM CHANNEL;

CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG MECHANISM; GENE DELETION; GENE MUTATION; HEART MUSCLE CELL; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; WILD TYPE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; FLECAINIDE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 80052593585     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.251322     Document Type: Letter

References (10)

1. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res. 2011;109:291-295.
2. WatanabeH, Chopra N, LaverD, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-383.
3. 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011;4:128-135.
4. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, Jones PP, Zhong X, Guo A, Chen H, Zhang L, Zhu W, Yang D, Li X, Chen J, Gillis AM, Duff HJ, Cheng H, Feldman AM, Song LS, Fill M, Back TG, Chen SR. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca(2 +) release. Nat Med. Published online before print July 10, 2011. doi: 10.1038/nm.2406. http://www.nature.com/nm/journal/vaop/ncurrent/ full/nm.2406.html.
5. 2+ spark mass. J Mol Cell Cardiol. 2010; 48:293-301.
6. 2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol. Published online before print July 12, 2011. doi:10.1016/j.yjmcc.2011.07.002. http://www.sciencedirect. com/science/article/pii/S0022282811002665.
7. Kang G, Giovannone SF, Liu N, Liu FY, Zhang J, Priori SG, Fishman GI. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res. 2010;107:512-519.
8. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244-2254.
9. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, Saito A, Kurosaki K, Jouo K, Koujiro M, Konishi S, Matsuoka S, Oono T, Hayakawa S, Miura M, Ushinohama H, Shibata T, Niimura I. Catecholaminergic polymorphic ventricular tachycardia: electrocardio-graphic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66-70. (Pubitemid 36044293)
10. De Rosa G, Delogu AB, Piastra M, Chiaretti A, Bloise R, Priori SG. Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol. Pediatr Emerg Care. 2004;20:175-177. (Pubitemid 38381036)